Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor

International Journal of Pharmaceutics

Volumn 506, Issue 1-2, 2016, Pages 93-101

  Kim, Jin Cheul ^a,b   Kim, Kyeong Soo ^a,b   Kim, Dong Shik ^a   Jin, Sung Giu ^a   Kim, Dong Wuk ^a   Kim, Yong Il ^b   Park, Jae Hyun ^b   Kim, Jong Oh ^c   Yong, Chul Soon ^c   Youn, Yu Seok ^d   Woo, Jong Soo ^b   Choi, Han Gon ^a  

^a Hanyang University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Yeungnam University   (South Korea)

^d Sungkyunkwan University   (South Korea)

Author keywords

Bioavailability; HM30181 mesylate salt; Microcapsule; P glycoprotein inhibitor; Paclitaxel; Solubility

Indexed keywords

4 OXO 4H CHROMENE 2 CARBOXYLIC ACID [2 [2 4 [2 (6,7 DIMETHOXY 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]PHENYL 2H TETRAZOL 5 YL] 4,5 DIMETHOXY PHENYL]AMIDE; ACIDIFYING AGENT; ALCOHOL; DICHLOROMETHANE; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PHOSPHORIC ACID; POLYMER; SILICON DIOXIDE; SOLVENT; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 4-OXO-4H-CHROMENE-2-CARBOXYLIC ACID (2-(2-(4-(2-(6,7-DIMETHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHYL)-PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)AMIDE; BENZOPYRAN DERIVATIVE; DRUG CARRIER; HYDROXYPROPYLMETHYLCELLULOSE-LACTOSE MATRIX; ISOQUINOLINE DERIVATIVE; LACTOSE; MESYLIC ACID DERIVATIVE; METHYLCELLULOSE; MICROCAPSULE; POWDER;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FLOW RATE; MALE; MICROCAPSULE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; RAT; SPRAY DRYING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOLOGY; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BENZOPYRANS; BIOLOGICAL AVAILABILITY; CAPSULES; DRUG CARRIERS; ISOQUINOLINES; LACTOSE; MALE; MESYLATES; METHYLCELLULOSE; P-GLYCOPROTEINS; PACLITAXEL; PHOSPHORIC ACIDS; POLYMERS; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SOLUBILITY; TETRAZOLES;

EID: 84964584136     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.04.034     Document Type: Article

References (53)

1. K. Akiyama, N. Maishi, N. Ohga, Y. Hida, Y. Ohba, M.T. Alam, T. Kawamoto, H. Ohmura, K. Yamada, C. Torii, M. Shindoh, and K. Hida Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel Am. J. Pathol. 185 2 2015 572 580
2. H.K. Ahn, M. Jung, S.J. Sym, D.B. Shin, S.M. Kang, S.Y. Kyung, J.W. Park, S.H. Jeong, and E.K. Cho A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer Cancer Chemother. Pharmacol. 74 2 2014 277 282
3. H.A. Bardelmeijer, M. Ouwehand, J.H. Beijnen, J.H. Schellens, and O. van Tellingen Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice Invest. New Drugs 22 3 2004 219 229
4. F. Bauer, T. Wanek, S. Mairinger, J. Stanek, M. Sauberer, C. Kuntner, Z. Parveen, P. Chiba, M. Müller, O. Langer, and T. Erker Interaction of HM30181A with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography Eur. J. Pharmacol. 696 2012 18 27
5. C.D. Britten, S.D. Baker, L.J. Denis, T. Johnson, R. Drengler, L.L. Siu, K. Duchin, J. Kuhn, and E.K. Rowinsky Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel Clin. Cancer Res. 6 9 2000 3459 3468
6. Q. Cai, X. Deng, Z. Li, D. An, T. Shen, and M. Zhong Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats Drug Deliv. 21 2015 1 7
7. S.W. Chae, S. Woo, J.H. Park, Y. Kwon, Y. Na, and H.J. Lee Xanthone analogues as potent modulators of intestinal P-glycoprotein Eur. J. Med. Chem. 93 2015 237 245
8. P. Gao, B.D. Rush, W.P. Pfund, T. Huang, J.M. Bauer, W. Morozowich, M.S. Kuo, and M.J. Hageman Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 92 12 2003 2386 2398
9. F. Fenyvesi, T. Kiss, E. Fenyvesi, L. Szente, S. Veszelka, M.A. Deli, J. Váradi, P. Fehér, Z. Ujhelyi, A. Tósaki, M. Vecsernyés, and I. Bácskay Randomly methylated β-cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer? J. Pharm. Sci. 100 11 2011 4734 4744
10. B. Fleisher, J. Unum, J. Shao, and G. An Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction? J. Pharm. Sci. 104 1 2015 266 275
11. J.J. Hendrikx, J.S. Lagas, E. Wagenaar, H. Rosing, J.H. Schellens, J.H. Beijnen, and A.H. Schinkel Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation Br. J. Cancer 110 11 2014 2669 2676
12. L. Huang, C. Hu, M. Di Benedetto, R. Varin, J. Liu, L. Wang, J.P. Vannier, J. Jin, A. Janin, H. Lu, and H. Li Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib Onco Targets Ther. 7 2014 2249 2255
13. du H. Hwang, Y.I. Kim, K.H. Cho, B.K. Poudel, J.Y. Choi, D.W. Kim, Y.J. Shin, O.N. Bae, A.M. Yousaf, C.S. Yong, J.O. Kim, and H.G. Choi A novel solid dispersion system for natural product-loaded medicine: silymarin-loaded solid dispersion with enhanced oral bioavailability and hepatoprotective activity J. Microencapsul. 31 7 2014 619 626
14. K.M. Joo, K. Park, D.S. Kong, S.Y. Song, M.H. Kim, G.S. Lee, M.S. Kim, and D.H. Nam Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor Oncol. Rep. 19 1 2008 17 23
15. K.M. Joo, S.Y. Song, K. Park, M.H. Kim, J. Jin, B.G. Kang, M.J. Jang, G.S. Lee, M.S. Kim, and D.H. Nam Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors Int. J. Oncol. 33 4 2008 705 712
16. B.S. Kang, S.E. Lee, C.L. Ng, C.W. Cho, and J.S. Park Determination of preparation parameters for albendazole-loaded nanoparticles using chitosan and tripolyphosphate J. Pharm. Invest. 45 3 2015 265 269
17. D.W. Kim, M.S. Kwon, A.M. Yousaf, P. Balakrishnan, J.H. Park, D.S. Kim, B.J. Lee, Y.J. Park, C.S. Yong, J.O. Kim, and H.G. Choi Comparison of a solid SMEDDS and solid dispersion for enhanced stability and bioavailability of clopidogrel napadisilate Carbohydr. Polym. 114 2014 365 3674
18. D.W. Kim, T. Ramasamy, J.Y. Choi, J.H. Kim, C.S. Yong, J.O. Kim, and H.G. Choi The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles Int. J. Nanomed. 9 2014 3815 3824
19. K.S. Kim, S.G. Jin, O. Mustapha, A.M. Yousaf, D.W. Kim, Y.H. Kim, J.O. Kim, C.S. Yong, J.S. Woo, and H.G. Choi Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs Int. J. Pharm. 490 2015 273 280
20. Y.H. Kim, D.W. Kim, M.S. Kwon, T.K. Kwon, J.H. Park, S.G. Jin, K.S. Kim, J.H. Yong Il Kim Park, J.O. Kim, C.S. Yong, J.S. Woo, and H.G. Choi Novel montelukast sodium-loaded clear oral solution prepared with hydroxypropyl-β-cyclodextrin as a solubilizer and stabilizer: enhanced stability and bioequivalence to commercial granules in rats J. Incl. Phenom. Macrocycl. Chem. 82 2015 479 487
21. H. Kouchakzadeh, M.S. Safavi, and S.A. Shojaosadati Efficient delivery of therapeutic agents by using targeted albumin nanoparticles Adv. Protein Chem. Struct. Biol. 98 2015 121 143
22. K.K. Kumar, L. Priyanka, K. Gnananath, P.R. Babu, and S. Sujatha Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats Eur. J. Drug Metab. Pharmacokinet. 40 3 2015 267 276
23. J.O. Kwak, S.H. Lee, G.S. Lee, M.S. Kim, Y.G. Ahn, J.H. Lee, S.W. Kim, K.H. Kim, and M.G. Lee Selective inhibition of MDR1 (ABCB1) by HM30181A increases oral bioavailability and therapeutic efficacy of paclitaxel Eur. J. Pharmacol. 627 2010 92 98
24. C.K. Lee, and J.S. Choi Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats Pharmacology 85 6 2010 350 356
25. H.J. Lee, D.S. Heo, J.Y. Cho, S.W. Han, H.J. Chang, H.G. Yi, T.E. Kim, S.H. Lee, D.Y. Oh, S.A. Im, I.J. Jang, and Y.J. Bang A phase I study of oral paclitaxel with a novel p-glycoprotein inhibitor, HM30181A, in patients with advanced solid cancer Cancer Res Treat. 46 3 2014 234 242
26. J.O. Lee, Y.S. Youn, D.K. Lee, K.H. Cha, and E.S. Lee Development of poly(lactic-co-glycolic acid) microparticles with pH-sensitive drug release behaviors J. Pharm. Invest. 45 2 2015 151 156
27. K.W. Lee, K.H. Lee, D.Y. Zang, Y.I. Park, D.B. Shin, J.W. Kim, S.A. Im, S.A. Koh, K.S. Yu, J.Y. Cho, J.A. Jung, and Y.J. Bang Phase I/II study of weekly oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer Oncologist 20 8 2015 896 897
28. C. Nehate, S. Jain, A. Saneja, V. Khare, N. Alam, R.D. Dubey, and P.N. Gupta Paclitaxel formulations: challenges and novel delivery options Curr. Drug Deliv. 11 6 2014 666 686
29. A.O. Nornoo, H. Zheng, L.B. Lopes, B. Johnson-Restrepo, K. Kannan, and R. Reed Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies Eur. J. Pharm. Biopharm. 71 2 2009 310 317
30. I.B. Paek, H.Y. Ji, M.S. Kim, G.S. Lee, and H.S. Lee Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry J. Sep. Sci. 29 5 2006 628 634
31. J.H. Park, J.H. Park, H.J. Hur, J.S. Woo, and H.J. Lee Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats Eur. J. Pharm. Sci. 45 3 2012 296 301
32. K. Patel, A. Patil, M. Mehta, V. Gota, and P. Vavia Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity Int. J. Pharm. 472 1-2 2014 214 223
33. R. Pradhan, T. Ramasamy, J.Y. Choi, J.H. Kim, B.K. Poudel, J.W. Tak, N. Nukolova, H.G. Choi, C.S. Yong, and J.O. Kim Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin Carbohydr. Polym. 123 2015 313 323
34. T. Ramasamy, J.Y. Choi, H.J. Cho, S.K. Umadevi, B.S. Shin, H.G. Choi, C.S. Yong, and J.O. Kim Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo characterization Pharm. Res. 32 6 2015 1947 1956
35. T. Ramasamy, T.H. Tran, J.Y. Choi, H.J. Cho, J.H. Kim, C.S. Yong, H.G. Choi, and J.O. Kim Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery Carbohydr. Polym. 102 2014 653 661
36. R. Rashid, D.W. Kim, A.M. Yousaf, O. Mustapha, F.U. Din, J.H. Park, C.S. Yong, Y.K. Oh, Y.S. Youn, J.O. Kim, and H.G. Choi Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe Int. J. Nanomed. 10 2015 6147 6159
37. R. Rashid, D.W. Kim, F.U. Din, O. Mustapha, A.M. Yousaf, J.H. Park, J.O. Kim, C.S. Yong, and H.G. Choi Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion Carbohydr. Polym. 130 2015 26 31
38. Y.G. Seo, D.H. Kim, T. Ramasamy, J.H. Kim, N. Marasini, Y.K. Oh, D.W. Kim, J.K. Kim, C.S. Yong, J.O. Kim, and H.G. Choi Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect Int. J. Pharm. 452 2013 412 420
39. Y.G. Seo, D.W. Kim, W.H. Yeo, T. Ramasamy, Y.K. Oh, Y.J. Park, J.A. Kim, D.H. Oh, S.K. Ku, J.K. Kim, C.S. Yong, J.O. Kim, and H.G. Choi Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect Pharm. Res. 30 7 2013 1860 1870
40. S. Shanmugam, H.T. Im, Y.T. Sohn, Y.I. Kim, J.H. Park, E.S. Park, and J.S. Woo Enhanced oral bioavailability of paclitaxel by solid dispersion granulation Drug Dev. Ind. Pharm. 41 11 2015 1864 1876
41. R.K. Thapa, J.Y. Choi, B.K. Poudel, T.T. Hiep, S. Pathak, B. Gupta, H.G. Choi, C.S. Yong, and J.O. Kim Multilayer-coated liquid crystalline nanoparticles for effective sorafenib delivery to hepatocellular carcinoma ACS Appl. Mater. Interfaces 7 36 2015 20360 20368
42. K.K. To, D.C. Poon, Y. Wei, F. Wang, G. Lin, and L.W. Fu Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia Biochem. Pharmacol. 97 1 2015 27 37
43. T.H. Tran, B.K. Poudel, N. Marasini, J.S. Woo, H.G. Choi, C.S. Yong, and J.O. Kim Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique Arch. Pharm. Res. 36 1 2013 86 93
44. T.H. Tran, T. Ramasamy, J.Y. Choi, H.T. Nguyen, T.T. Pham, J.H. Jeong, S.K. Ku, H.G. Choi, C.S. Yong, and J.O. Kim Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells Int. J. Nanomed. 10 2015 5249 5262
45. C.P. Wan, K. Letchford, J.K. Jackson, and H.M. Burt The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance Int. J. Nanomed. 8 2013 379 391
46. T. Wang, Y. Sun, W. Ma, Z. Yang, J. Yang, J. Liu, H. Fan, Y. Yang, J. Gu, J.P. Fawcett, and Y. Guo Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo Mol. Pharm. 12 1 2015 1 9
47. A.T. Wang, D.S. Liang, Y.J. Liu, and X.R. Qi Roles of ligand and TPGS of micelles in regulating internalization: penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumors Biomaterials 53 2015 160 172
48. H. Wang, G. Cheng, Y. Du, L. Ye, W. Chen, L. Zhang, T. Wang, J. Tian, and F. Fu Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation Mol. Med. Rep. 7 3 2013 947 952
49. Y.D. Yan, N. Marasini, Y.K. Choi, J.O. Kim, J.S. Woo, C.S. Yong, and H.G. Choi Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS) Eur. J. Drug Metab. Pharmacokinet. 37 3 2012 217 224
50. K.Y. Yang, H. Hwang du, A.M. Yousaf, D.W. Kim, Y.J. Shin, O.N. Bae, Y.I. Kim, J.O. Kim, C.S. Yong, and H.G. Choi Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation Int. J. Nanomed. 8 2013 3333 3343
51. S. Yang, R.N. Gursoy, G. Lambert, and S. Benita Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors Pharm. Res. 21 2 2004 261 270
52. A.M. Yousaf, D.W. Kim, Y.K. Oh, C.S. Yong, J.O. Kim, and H.G. Choi Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation Int. J. Nanomed. 10 2015 1819 1830
53. Y. Zang, C.J. Kirk, and D.E. Johnson Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors Cancer Biol. Ther. 15 9 2014 1142 1152